70 completed. 70 Phase 1, 24 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 70 | Completed 70 |
| Phase 2 | 24 | Completed 24 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study of Safety of H1337 in Healthy Volunteers H-1337 1.0% - Glaucoma Open-Angle Primary, Ocular Hypertension | Phase 1 | Completed | D. Western Therapeutics Institute, Inc. | 17 | 2024-09-16 | 2025-02-11 |
| Effect of Latanoprost on Optic Nerve Perfusion Latanoprost (0.005%) - Treatment Outcome | Phase 1 | Completed | Zagazig University | 46 | 2024-06-24 | 2024-10-08 |
| A Study of PER-001 in Participants With Open-Angle Glaucoma PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham - Open-angle Glaucoma | Phase 1 / Phase 2 | Completed | Perfuse Therapeutics, Inc. | 33 | 2023-05-25 | 2026-06-05 |
| A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma ONL1204 Ophthalmic solution (Dose A), ONL1204 Ophthalmic solution (Dose B), Sham procedure - Open Angle Glaucoma | Phase 1 | Completed | ONL Therapeutics | 25 | 2022-05-02 | 2024-10-29 |
| Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension. 100ng/day PA5346 Latanoprost FA SR Ocular Implant - Open Angle Glaucoma, Ocular Hypertension | Phase 1 | Completed | PolyActiva Pty Ltd | 1 | 2022-03-04 | 2024-04-12 |
| Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930 D565, D930 - Glaucoma | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2022-01-19 | 2023-01-05 |
| Safety and Tolerability of NTX-101 in Korean Healthy Volunteers NTX-101, Placebo - Healthy Volunteers | Phase 1 | Completed | Pinotbio, Inc. | 36 | 2021-03-02 | 2022-04-20 |
| Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma PA5108 Latanoprost FA SR Ocular Implant - Open Angle Glaucoma | Phase 1 | Completed | PolyActiva Pty Ltd | 37 | 2020-03-11 | 2025-11-20 |
| Safety and IOP-Lowering Effects of WB007 WB007 0.05%, WB007 0.15%, WB007 0.4% - Glaucoma, Primary Open Angle, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Bausch & Lomb Incorporated | 77 | 2019-11-14 | 2025-03-27 |
| Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma BGS goggles - Glaucoma, Ocular Hypertension | Phase 1 | Completed | Stanford University | 11 | 2019-07-23 | 2022-11-23 |
| Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® PRO-122, Krytantek Ofteno® - Glaucoma | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 24 | 2019-05-02 | 2019-12-13 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 1 | Completed | Aerpio Therapeutics | 91 | 2019-05-02 | 2020-02-25 |
| Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® PRO 179, Travatan 0.004 % Ophthalmic Solution - Glaucoma | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 24 | 2019-04-24 | 2019-12-12 |
| Study of ANX007 in Participants With Primary Open-angle Glaucoma 2.5mg ANX007, 5.0mg ANX007, Sham Procedure - Open Angle Glaucoma | Phase 1 | Completed | Annexon, Inc. | 17 | 2018-07-25 | 2020-08-20 |
| Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma PA5108 - Open-angle Glaucoma | Phase 1 | Completed | PolyActiva Pty Ltd | 8 | 2018-07-24 | 2020-09-16 |
| CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension OTX-TIC - Ocular Hypertension, Open Angle Glaucoma | Phase 1 | Completed | Ocular Therapeutix, Inc. | 19 | 2018-04-25 | 2024-10-01 |
| Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma ANX007 - Open-angle Glaucoma | Phase 1 | Completed | Annexon, Inc. | 9 | 2018-03-23 | 2020-08-20 |
| H-1337 Ophthalmic Solution Phase 1/2 H-1337 Placebo, H-1337 [1], H-1337 [2] - Glaucoma, Open-Angle | Phase 1 / Phase 2 | Completed | Allysta Pharmaceutical | 87 | 2018-03-15 | 2022-07-12 |
| Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt brinzolamide 1% ophthalmic suspension, Azopt 1% - Glaucoma, Open Angle or Ocular Hypertension | Phase 1 / Phase 2 | Completed | Bausch & Lomb Incorporated | 637 | 2018-02-28 | 2023-05-09 |
| Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses timolol maleate and dorzolamide hydrochloride - Glaucoma | Phase 1 | Completed | University of Florida | 2 | 2018-01-18 | 2021-12-02 |
Showing 20 of 70. Sign in to see all of them.
Glaucoma, Open-Angle (38) · Ocular Hypertension (38) · Eye Diseases (4) · Cataract (1) · Glaucoma, Neovascular (1) · Hydrophthalmos (1) · Macular Edema (1) · Optic Neuropathy, Ischemic (1) · Retinal Degeneration (1) · Uveal Melanoma (1) · Uveitis (1) · Uveitis, Posterior (1)
Eye Diseases (66) · Ocular Hypertension (32) · Retinal Diseases (2) · Uveal Diseases (2) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cranial Nerve Diseases (1) · Eye Abnormalities (1) · Eye Diseases, Hereditary (1) · Eye Neoplasms (1) · Glaucoma, Open-Angle (1) · Infant, Newborn, Diseases (1) · Lens Diseases (1)
Latanoprost (7) · Timolol (4) · Bimatoprost (3) · Ranibizumab (3) · Ophthalmic Solutions (2) · dorzolamide (2) · Bosentan (1) · Brimonidine Tartrate (1) · Brimonidine Tartrate, Timolol Maleate Drug Combination (1) · Culture Techniques (1) · Ethacrynic Acid (1) · Hanks Balanced Salt Solution (1) · Hyaluronic Acid (1) · INO-8875 (1) · ISTH0036 (1)
Allergan (3) · PolyActiva Pty Ltd (3) · Santen Inc. (3) · Alcon Research (2) · Annexon, Inc. (2) · Bausch & Lomb Incorporated (2) · Chong Kun Dang Pharmaceutical (2) · ForSight Vision5, Inc. (2) · Hoffmann-La Roche (2) · Laboratorios Sophia S.A de C.V. (2) · Merck Sharp & Dohme LLC (2) · Ocular Therapeutix, Inc. (2) · Sylentis, S.A. (2) · Aerpio Therapeutics (1) · Allysta Pharmaceutical (1)
United States (38) · Australia (4) · South Korea (4) · Spain (4) · Austria (3) · Germany (3) · Mexico (3) · New Zealand (3) · United Kingdom (3) · Brazil (2) · Israel (2) · Singapore (2) · South Africa (2) · Azerbaijan (1) · Belgium (1)
Eric Humphriss (2) · Jeffrey L Goldberg, MD, PhD (2) · Anne Rubin (1) · Auli Ropo (1) · Barrett Katz, MD (1) · Belen Sadaba, MD, PhD (1) · David G Callanan, MD (1) · David Wirta, MD (1) · Ehud Asia, Prof. (1) · Elmar Kasimov, Professor (1)
PMID 34707360, PMID 20570237, PMID 26453641, PMID 29802818, PMID 33469852, PMID 34780798, PMID 35643967, PMID 35696700, PMID 35943114, PMID 36055467, PMID 36912740
2008 (1), 2014 (1)